Evaluation of Effects of Exercise Training and ARB in DM Patients
Evaluation of Effects of Exercise Training and ARB in DM Patients
The aims of this clinical trial are to assess the impacts on vascular function tests and
 circulating biomarkers of a short-term (12-week) low-to-median intensity exercise training or
 ARBs treatment in patients with DM and hypertension.
Inclusion criteria: type II diabetic and hypertensive patients who are aged 30 to 70 year-old
 with HbA1c ≤ 8.0 % and systolic blood pressure ≥ 140 mmHg. Neither ACEI nor ARB is
 administrated in recent 6 months. None has significant concomitant systemic diseases such as
 active infection, malignancy, hepatic or significant renal dysfunction at the time of
 enrollment (i.e. total bilirubin > 3 mg/dl，ALT > 2.5 times the upper limit of normal range
 and creatinine > 3 mg/dl in our hospital). Information regarding smoking, hypertension,
 hyperlipidemia as well as history of cardiovascular disease is obtained from all subjects. No
 other medication will be modified during the study period. After enrollment, patients are
 assessed to (1) olmesartan (20 mg per day, with titration), (2) life modification/exercise
 training for 12 weeks. Vascular function and exercise capacity studies, and peripheral blood
 testing are performed at baseline and at 12- week follow-up. Data are collected as mean ± SD
 showing comparison between groups by use of 2-sample t test and chi-square analysis for
 continuous and categorical variables, respectively. Adjust for the HbA1c level will be
 adjusted using simple adjustment method (ANCOVA or equivalent regression analysis) while
 doing the data analysis. Changes between baseline and follow-up measurements are assessed by
 paired t test. The frequencies of adverse effects between groups will also be comparing by
 2-sample t test. A p value <0.05 is defined as statistically significant.
Inclusion Criteria:

 -  patients with diabetes mellitus and hypertension

 -  age 30-70 years，systolic blood pressure 140-160 mmHg and HbA1c ≤ 8%,

 -  no history of ACEI or ARB use within 6 months

 Exclusion Criteria:

 -  active cardiovascular diseases

 -  severe hepatic

 -  renal dysfunction (CRE ≥ 3 mg/dl，T-Bil ≥ 3 mg/dl)